JP7043392B2 - 臨床製剤 - Google Patents

臨床製剤 Download PDF

Info

Publication number
JP7043392B2
JP7043392B2 JP2018508674A JP2018508674A JP7043392B2 JP 7043392 B2 JP7043392 B2 JP 7043392B2 JP 2018508674 A JP2018508674 A JP 2018508674A JP 2018508674 A JP2018508674 A JP 2018508674A JP 7043392 B2 JP7043392 B2 JP 7043392B2
Authority
JP
Japan
Prior art keywords
solution
cells
hours
cell
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018508674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523682A (ja
JP2018523682A5 (zh
Inventor
ゲイ,ロジャー
ラトリフ,ジャドソン
サウスウィック,ロンマ,イー.
Original Assignee
アステラス インスティテュート フォー リジェネレイティブ メディシン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アステラス インスティテュート フォー リジェネレイティブ メディシン filed Critical アステラス インスティテュート フォー リジェネレイティブ メディシン
Publication of JP2018523682A publication Critical patent/JP2018523682A/ja
Publication of JP2018523682A5 publication Critical patent/JP2018523682A5/ja
Priority to JP2021205350A priority Critical patent/JP7449915B2/ja
Application granted granted Critical
Publication of JP7043392B2 publication Critical patent/JP7043392B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04Preserving or maintaining viable microorganisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0621Eye cells, e.g. cornea, iris pigmented cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/60Buffer, e.g. pH regulation, osmotic pressure
JP2018508674A 2015-08-18 2016-08-18 臨床製剤 Active JP7043392B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021205350A JP7449915B2 (ja) 2015-08-18 2021-12-17 臨床製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562206821P 2015-08-18 2015-08-18
US62/206,821 2015-08-18
PCT/US2016/047545 WO2017031312A1 (en) 2015-08-18 2016-08-18 Clinical formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021205350A Division JP7449915B2 (ja) 2015-08-18 2021-12-17 臨床製剤

Publications (3)

Publication Number Publication Date
JP2018523682A JP2018523682A (ja) 2018-08-23
JP2018523682A5 JP2018523682A5 (zh) 2020-03-19
JP7043392B2 true JP7043392B2 (ja) 2022-03-29

Family

ID=56843032

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018508674A Active JP7043392B2 (ja) 2015-08-18 2016-08-18 臨床製剤
JP2021205350A Active JP7449915B2 (ja) 2015-08-18 2021-12-17 臨床製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021205350A Active JP7449915B2 (ja) 2015-08-18 2021-12-17 臨床製剤

Country Status (16)

Country Link
US (2) US11013808B2 (zh)
EP (1) EP3334415A1 (zh)
JP (2) JP7043392B2 (zh)
KR (3) KR102411018B1 (zh)
CN (1) CN108697641A (zh)
AU (2) AU2016308818B2 (zh)
BR (1) BR112018003031B1 (zh)
CA (1) CA2995977A1 (zh)
EA (2) EA202190722A1 (zh)
HK (1) HK1256839A1 (zh)
IL (3) IL299326A (zh)
MX (2) MX2018002038A (zh)
PH (1) PH12018500371A1 (zh)
SG (1) SG10201913250SA (zh)
TW (2) TWI833293B (zh)
WO (1) WO2017031312A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
US11891622B2 (en) 2014-12-30 2024-02-06 Cell Cure Neurosciences Ltd. RPE cell populations and methods of generating same
CA2980580C (en) 2015-03-23 2024-01-23 Astellas Institute For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
KR102411018B1 (ko) 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
WO2018003908A1 (ja) * 2016-06-30 2018-01-04 株式会社ヘリオス 移植用媒体
CA3086815A1 (en) * 2017-12-29 2019-07-04 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
KR20220054359A (ko) 2019-08-28 2022-05-02 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병을 치료하는 방법
WO2021041591A1 (en) 2019-08-28 2021-03-04 Astellas Institute For Regenerative Medicine Compositions and methods of treating vascular diseases
EP4051785A1 (en) 2019-10-30 2022-09-07 Astellas Institute for Regenerative Medicine Methods for producing retinal pigment epithelium cells
JP7018527B1 (ja) 2020-12-16 2022-02-10 アニコム先進医療研究所株式会社 細胞の保存方法および細胞懸濁液
CA3225810A1 (en) * 2021-07-15 2023-01-19 Joseph Piccirilli Preservative composition for nucleic acids and biological samples and methods of use
WO2023176906A1 (ja) * 2022-03-16 2023-09-21 住友ファーマ株式会社 移植用媒体
WO2024019962A1 (en) 2022-07-18 2024-01-25 Astellas Institute For Regenerative Medicine Methods of treating brain injury
WO2024044134A1 (en) 2022-08-23 2024-02-29 Astellas Institute For Regenerative Medicine Photoreceptor rescue cell (prc) compositions and methods for treatment of ocular disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030216431A1 (en) 2002-05-17 2003-11-20 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
JP2011500024A (ja) 2007-10-12 2011-01-06 アドバンスド セル テクノロジー, インコーポレイテッド Rpe細胞を生成する改良された方法およびrpe細胞の組成物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
DE69227179D1 (de) * 1992-03-27 1998-11-05 Chen Chung Ho Mittel für Gewebe zur Erhaltung der Lebensfähigkeit und biologische Funktionen in der Chirurgie und Lagerung
KR100267604B1 (ko) 1993-06-04 2000-11-01 이 세갈 폴 혈장 유사 용액
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
KR100384188B1 (ko) * 1997-08-22 2003-06-18 시미즈 세이야꾸 가부시키가이샤 글루코스 함유 제제
GB2336109A (en) 1998-04-07 1999-10-13 Univ Bristol Ophthalmic Irrigating Solution
CA2396130C (en) * 2000-01-11 2008-03-11 Ophtecs Corporation Preparation of irrigating solution for ocular surgery
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
CN104434979A (zh) 2004-01-23 2015-03-25 先进细胞技术公司 用于治疗视网膜变性病的改良模式
CN102660495A (zh) 2006-04-14 2012-09-12 先进细胞技术公司 血管瘤集落形成细胞
EP2054506A1 (en) 2006-08-15 2009-05-06 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
KR101803562B1 (ko) 2008-05-06 2017-12-01 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
KR101923290B1 (ko) 2008-05-06 2018-11-28 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포 및 비-생착성 혈관 세포
IL301479A (en) 2009-11-17 2023-05-01 Astellas Inst For Regenerative Medicine Methods for preparing human RPE cells and pharmaceutical preparations of human RPE cells
AU2010325811A1 (en) 2009-12-04 2012-06-21 Stem Cell & Regenerative Medicine International, Inc. Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
CA3080368A1 (en) 2009-12-04 2011-06-09 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
HUE054517T2 (hu) 2010-07-23 2021-09-28 Astellas Inst For Regenerative Medicine Eljárások sejtek ritka alpopulációinak detektálására és nagymértékben tisztított sejtkészítmények
WO2013074681A1 (en) 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Pharmaceutical preparations of human rpe cells and uses thereof
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
PT2785359T (pt) 2011-11-30 2018-11-06 Astellas Inst For Regenerative Medicine Células estromais mesenquimatosas e usos relacionados com as mesmas
PL2788472T3 (pl) 2011-12-06 2019-06-28 Astellas Institute For Regenerative Medicine Sposób ukierunkowanego różnicowania z wytwarzaniem komórek śródbłonka rogówki
CN103783031B (zh) 2012-10-29 2015-11-18 四川新生命干细胞科技股份有限公司 一种细胞保存液
AU2013201546B2 (en) 2012-12-18 2014-10-23 Gambro Lundia Ab Dialysis composition
ES2896354T3 (es) 2012-12-21 2022-02-24 Astellas Inst For Regenerative Medicine Métodos para la producción de plaquetas a partir de células madre pluripotentes
US20160175361A1 (en) 2014-03-14 2016-06-23 Advanced Cell Technology, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175362A1 (en) 2014-03-14 2016-06-23 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
IL294897B2 (en) 2013-03-15 2024-03-01 Astellas Inst For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
JP6778181B2 (ja) 2014-09-05 2020-10-28 アステラス インスティテュート フォー リジェネレイティブ メディシン 網膜神経節細胞およびその前駆体
CA2980580C (en) 2015-03-23 2024-01-23 Astellas Institute For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
KR102411018B1 (ko) * 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
WO2021041591A1 (en) 2019-08-28 2021-03-04 Astellas Institute For Regenerative Medicine Compositions and methods of treating vascular diseases
KR20220054359A (ko) 2019-08-28 2022-05-02 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병을 치료하는 방법
EP4051785A1 (en) 2019-10-30 2022-09-07 Astellas Institute for Regenerative Medicine Methods for producing retinal pigment epithelium cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030216431A1 (en) 2002-05-17 2003-11-20 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
JP2011500024A (ja) 2007-10-12 2011-01-06 アドバンスド セル テクノロジー, インコーポレイテッド Rpe細胞を生成する改良された方法およびrpe細胞の組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Arq Bras Oftalmol.,2008年,Vol.71, No.5,pp.644-650
IOVS,2010年,Vol.51, No.12,pp.6394-6400

Also Published As

Publication number Publication date
US20190358330A9 (en) 2019-11-28
IL291163B2 (en) 2023-05-01
AU2016308818B2 (en) 2022-04-21
IL257551A (en) 2018-04-30
KR102651291B1 (ko) 2024-03-26
TW202245816A (zh) 2022-12-01
IL291163A (en) 2022-05-01
NZ740608A (en) 2023-09-29
EA201890516A1 (ru) 2018-09-28
CN108697641A (zh) 2018-10-23
AU2022206757A1 (en) 2022-08-18
BR112018003031B1 (pt) 2023-12-26
KR20230058544A (ko) 2023-05-03
JP2018523682A (ja) 2018-08-23
SG10201913250SA (en) 2020-03-30
WO2017031312A1 (en) 2017-02-23
BR112018003031A2 (pt) 2018-09-18
IL299326A (en) 2023-02-01
CA2995977A1 (en) 2017-02-23
TWI772270B (zh) 2022-08-01
KR20220090583A (ko) 2022-06-29
US20210275673A1 (en) 2021-09-09
TW201717912A (zh) 2017-06-01
IL257551B (en) 2022-04-01
MX2018002038A (es) 2018-07-06
TWI833293B (zh) 2024-02-21
KR20180048722A (ko) 2018-05-10
US11013808B2 (en) 2021-05-25
JP2022040140A (ja) 2022-03-10
US20190030168A1 (en) 2019-01-31
PH12018500371A1 (en) 2018-08-29
JP7449915B2 (ja) 2024-03-14
MX2022010363A (es) 2022-09-21
IL291163B1 (en) 2023-01-01
EA202190722A1 (ru) 2021-10-29
EA037915B1 (ru) 2021-06-07
HK1256839A1 (zh) 2019-10-04
EP3334415A1 (en) 2018-06-20
US11957754B2 (en) 2024-04-16
KR102411018B1 (ko) 2022-06-20
AU2016308818A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
JP7043392B2 (ja) 臨床製剤
JP7081016B2 (ja) ヒトrpe細胞医薬品およびその使用
KR102073730B1 (ko) 인간 rpe 세포의 생산 방법 및 인간 rpe 세포의 제약 제제
US4443432A (en) Ophthmalic irrigating solution
US4550022A (en) Tissue irrigating solution
JP2008538752A (ja) 角膜組織を生体外保存するための組成物および方法
JPWO2020045642A1 (ja) 眼細胞を保存または培養するための組成物および方法
US20060177524A1 (en) Ocular irrigating solution
NZ740608B2 (en) Clinical formulations
US20210220515A1 (en) Viscoelastic agent material
WO2024044608A1 (en) Cell cryopreservative formulations and methods of use
JP2015514107A (ja) 角膜増殖のための組成物及び方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211217

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211217

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220207

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220316

R150 Certificate of patent or registration of utility model

Ref document number: 7043392

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150